Minneapolis—A retrospective database study of insurance claims for 63,000 adults with schizophrenia who were prescribed certain oral atypical antipsychotic (AA) medications found that less than one-third (approximately 29.4%) remained...
Minneapolis—A retrospective database study of insurance claims for 63,000 adults with schizophrenia who were prescribed certain oral atypical antipsychotic (AA) medications found that less than one-third (approximately 29.4%) remained...
Edmund Pezalla, MD, MPH, CEO of Enlightenment Bioconsult, formerly of Aetna, discusses treatment options for multiple sclerosis (MS), highlights results from the ASCLEPIOS I and II studies, and notes why this data can be useful for payers. Dr...
Edmund Pezalla, MD, MPH, CEO of Enlightenment Bioconsult, formerly of Aetna, discusses treatment options for multiple sclerosis (MS), highlights results from the ASCLEPIOS I and II studies, and notes why this data can be useful for payers. Dr...
Hearing loss is the third most prevalent chronic condition among older adults and is tied to cognitive decline, poor physical health, and increased hospitalizations. Yet, many cannot afford a hearing aid, which typically cost around $2500.
Hearing loss is the third most prevalent chronic condition among older adults and is tied to cognitive decline, poor physical health, and increased hospitalizations. Yet, many cannot afford a hearing aid, which typically cost around $2500.
In this interview, Ferdinand Formoso, DO, discusses the role of condoliase as a minimally invasive treatment for lumbar disc herniation, its safety profile, potential areas for further research, and its ability to address unmet needs in spine...
In this interview, Ferdinand Formoso, DO, discusses the role of condoliase as a minimally invasive treatment for lumbar disc herniation, its safety profile, potential areas for further research, and its ability to address unmet needs in spine...
In this interview, Michael Kolodziej, MD, discusses strategies for enhancing biosimilar adoption in the US, emphasizing lessons from global markets, the importance of payer flexibility, and the need for collaboration to reduce costs and...
In this interview, Michael Kolodziej, MD, discusses strategies for enhancing biosimilar adoption in the US, emphasizing lessons from global markets, the importance of payer flexibility, and the need for collaboration to reduce costs and...
In this interview, Michael Kolodziej, MD, discusses the role of biosimilars in value-based care models, their relationship with targeted therapies, and the impact of policy changes and market trends on biosimilar adoption and cost...
In this interview, Michael Kolodziej, MD, discusses the role of biosimilars in value-based care models, their relationship with targeted therapies, and the impact of policy changes and market trends on biosimilar adoption and cost...
John Hennessy, MBA, discusses the complexities of biosimilar adoption, highlighting potential cost savings, payer strategies, challenges in provider and patient acceptance, regulatory impacts, and the critical need for sustainable market...
John Hennessy, MBA, discusses the complexities of biosimilar adoption, highlighting potential cost savings, payer strategies, challenges in provider and patient acceptance, regulatory impacts, and the critical need for sustainable market...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...